On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...

Outlook Therapeutics ( ($OTLK) ) has provided an update. On January 31, 2025, Outlook Therapeutics entered into a Securities Purchase Agreement ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as Chairman ...

Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company that focuses on retinal diseases saw its stock price upped 18.24% on Friday after its financial results for fiscal years 2024 ...

Outlook Therapeutics, Inc. announced the approval and upcoming launch of LYTENAVA™ (bevacizumab gamma), the first authorized ophthalmic formulation of bevacizumab for treating wet age-related ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company with a current market capitalization of $50.3 million, announced the appointment of Faisal G. Sukhtian as ...